A single-center chart review found that postmenopausal women with osteoporosis may be started on antiresorptive therapy without having had secondary causes ruled out.
Among people with type 2 diabetes who received a GLP-1 receptor agonist, there was less correlation between this treatment and thyroid cancer than among people with type 2 diabetes treated with insulin.